Cancer Treatment
New findings from Germany and the South Korea in the area of cancer treatment detailed
Published in Gene Therapy Weekly, November 2nd, 2006
Study 1: A study from Germany has reported on the inhibition of the multidrug-resistant (MDR) phenotype by targeting YB-1 with a conditionally oncolytic adenovirus.
"Bearing in mind the limited success of available treatment modalities for the therapy of multidrug-resistant tumor cells, alternative and complementary strategies need to be developed. It is known that the transcriptional activation of genes, such as MDR1 and MRP1, which play a major role in the development of a multidrug-resistant phenotype in tumor cells, involves the Y-box protein YB-1.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-11-02)
More Articles from Gene Therapy Weekly
- Apoptosis
Apoptosis differentially regulated by gene overexpression - Cancer Therapy
Adenovirus vector use eliminates an established tumor - Cardiology
Myotonic dystrophy involves RNA toxicity and cardiac conduction defects - Gene Targeting
Conventional gene targeting protocols lead to loss of targeted cells - Genetics & Genomics
Human artificial chromosomes are stably maintained in mitosis - Acute Myeloid Leukemia Cell Biology
Research from Children's Cancer Research Institute provides new data on acute myeloid leukemia cell biology - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
